Double maintains 4 strategies that include TECH - Bio-Techne Corp.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -49.07% | $200.94M | 0.85% |
| VIXM | -46.45% | $22.99M | 0.85% |
| TAIL | -46.08% | $94.90M | 0.59% |
| BTAL | -43.43% | $310.24M | 1.43% |
| IVOL | -35.26% | $341.06M | 1.02% |
| ULST | -20.90% | $592.71M | 0.2% |
| FTSD | -18.75% | $233.24M | 0.25% |
| XONE | -17.89% | $629.16M | 0.03% |
| FXY | -16.87% | $798.58M | 0.4% |
| STPZ | -16.85% | $443.85M | 0.2% |
| CLIP | -16.42% | $1.51B | 0.07% |
| SPTS | -16.15% | $5.78B | 0.03% |
| TPMN | -15.62% | $30.86M | 0.65% |
| SHYM | -14.17% | $355.87M | 0.35% |
| XHLF | -13.70% | $1.73B | 0.03% |
| UTWO | -13.02% | $376.64M | 0.15% |
| SCHO | -11.81% | $10.92B | 0.03% |
| VTIP | -11.64% | $15.19B | 0.03% |
| IBTH | -11.58% | $1.62B | 0.07% |
| VGSH | -10.99% | $22.70B | 0.03% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPH | 75.61% | $728.37M | 0.4% |
| BBH | 75.28% | $345.62M | 0.35% |
| IBB | 73.89% | $5.59B | 0.45% |
| FBT | 73.61% | $1.05B | 0.54% |
| MOAT | 72.46% | $12.98B | 0.47% |
| FXH | 71.74% | $891.10M | 0.62% |
| PBE | 71.46% | $233.59M | 0.58% |
| GNOM | 68.84% | $45.27M | 0.5% |
| FHLC | 68.24% | $2.46B | 0.084% |
| VHT | 68.14% | $15.49B | 0.09% |
| IYH | 67.11% | $2.76B | 0.39% |
| SMOT | 66.95% | $403.05M | 0.49% |
| DSTL | 66.68% | $1.82B | 0.39% |
| FIW | 66.38% | $1.91B | 0.51% |
| XHE | 65.62% | $168.87M | 0.35% |
| JVAL | 64.73% | $532.35M | 0.12% |
| QQQJ | 64.61% | $633.38M | 0.15% |
| RSP | 64.55% | $74.68B | 0.2% |
| XLV | 64.53% | $34.28B | 0.09% |
| NUMV | 64.44% | $383.56M | 0.31% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CARY | 0.01% | $347.36M | 0.8% |
| IBTL | 0.04% | $386.59M | 0.07% |
| FLMI | -0.15% | $745.34M | 0.3% |
| CANE | -0.27% | $11.17M | 0.29% |
| CMBS | -0.34% | $456.43M | 0.25% |
| NEAR | -0.51% | $3.35B | 0.25% |
| VGIT | -0.69% | $31.83B | 0.04% |
| BSV | 0.78% | $38.00B | 0.03% |
| SHY | -0.87% | $23.69B | 0.15% |
| SCHR | 1.05% | $10.87B | 0.03% |
| CTA | 1.08% | $1.07B | 0.76% |
| SPTI | 1.20% | $8.68B | 0.03% |
| BSMR | 1.22% | $258.73M | 0.18% |
| SGOV | -1.23% | $50.94B | 0.09% |
| SPSK | 1.33% | $326.14M | 0.5% |
| SMB | -1.45% | $276.89M | 0.07% |
| SHV | 1.66% | $20.75B | 0.15% |
| BNDX | -1.71% | $67.48B | 0.07% |
| USDU | 1.79% | $129.88M | 0.5% |
| IGOV | 1.83% | $1.25B | 0.35% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EXC | 0.14% | $43.84B | +22.86% | 3.60% |
| T | 0.15% | $195.43B | +46.18% | 4.11% |
| K | -0.41% | $27.64B | +41.46% | 2.87% |
| AWK | 0.61% | $27.95B | +5.15% | 2.18% |
| MCK | -0.62% | $89.38B | +23.75% | 0.40% |
| VHC | 0.78% | $74.47M | +193.32% | 0.00% |
| MKTX | -0.80% | $8.15B | -1.09% | 1.39% |
| NEUE | 0.83% | $60.89M | +31.91% | 0.00% |
| MVO | 0.96% | $69.92M | -35.18% | 21.79% |
| PRPO | 1.01% | $22.45M | +220.44% | 0.00% |
| DG | -1.32% | $25.17B | -9.90% | 2.08% |
| CREG | 1.48% | $5.73M | -77.49% | 0.00% |
| UUU | -1.60% | $7.33M | +132.47% | 0.00% |
| DUK | 1.63% | $91.66B | +11.97% | 3.55% |
| ED | -1.67% | $36.39B | +11.91% | 3.34% |
| MUSA | 1.71% | $8.57B | -10.31% | 0.44% |
| ZCMD | 1.85% | $28.79M | -11.91% | 0.00% |
| CCEC | 1.98% | $1.02B | +3.91% | 2.42% |
| PM | 1.99% | $281.34B | +72.03% | 3.00% |
| CPSH | 2.01% | $36.61M | +48.24% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -13.07% | $24.71B | +36.77% | 1.07% |
| CME | -9.55% | $99.84B | +44.13% | 1.75% |
| KR | -6.05% | $47.78B | +38.66% | 1.78% |
| HUSA | -5.74% | $20.46M | -9.15% | 0.00% |
| VSTA | -5.57% | $325.62M | +40.00% | 0.00% |
| MSIF | -4.49% | $772.77M | +36.75% | 7.52% |
| STG | -3.47% | $56.15M | +27.66% | 0.00% |
| COR | -2.52% | $57.58B | +33.69% | 0.73% |
| MO | -2.46% | $97.92B | +21.81% | 7.02% |
| TEF | -2.43% | $29.40B | +19.77% | 6.32% |
| GFI | -2.37% | $21.69B | +51.82% | 2.28% |
| GO | -2.33% | $1.34B | -34.12% | 0.00% |
| ED | -1.67% | $36.39B | +11.91% | 3.34% |
| UUU | -1.60% | $7.33M | +132.47% | 0.00% |
| DG | -1.32% | $25.17B | -9.90% | 2.08% |
| MKTX | -0.80% | $8.15B | -1.09% | 1.39% |
| MCK | -0.62% | $89.38B | +23.75% | 0.40% |
| K | -0.41% | $27.64B | +41.46% | 2.87% |
| EXC | 0.14% | $43.84B | +22.86% | 3.60% |
| T | 0.15% | $195.43B | +46.18% | 4.11% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RVTY | 80.90% | $11.61B | -8.92% | 0.29% |
| A | 80.44% | $34.11B | -8.34% | 0.84% |
| BRKR | 78.02% | $6.55B | -31.86% | 0.46% |
| MTD | 77.35% | $24.81B | -12.12% | 0.00% |
| TMO | 75.53% | $160.56B | -21.91% | 0.39% |
| IQV | 75.25% | $27.70B | -29.11% | 0.00% |
| DHR | 72.00% | $141.52B | -19.69% | 0.60% |
| BIO | 70.22% | $6.83B | -16.98% | 0.00% |
| WAT | 66.00% | $18.10B | +0.41% | 0.00% |
| QGEN | 65.86% | $10.46B | +12.29% | 0.52% |
| ILMN | 65.79% | $15.60B | -15.47% | 0.00% |
| TXG | 65.06% | $1.56B | -28.00% | 0.00% |
| AZTA | 64.76% | $1.48B | -39.63% | 0.00% |
| POWI | 64.04% | $3.19B | -24.92% | 1.45% |
| CRL | 63.48% | $7.76B | -26.92% | 0.00% |
| AVTR | 62.72% | $9.01B | -36.50% | 0.00% |
| SWK | 62.38% | $11.07B | -17.65% | 4.53% |
| ITW | 61.83% | $75.48B | +4.41% | 2.32% |
| RGEN | 60.79% | $6.82B | -1.04% | 0.00% |
| ENTG | 60.32% | $13.06B | -40.61% | 0.45% |
Finnhub
Bio-Techne Corporation announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under...
Finnhub
Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation , a global...
Finnhub
MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection...
Yahoo
Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII, a complex therapeutic target critical to Z
Finnhub
Bio-Techne Corporation announced that its Simple Western? Technology played a key role in supporting the FDA approval of ZEVASKYN? , the first autologous cell-based gene therapy for patients with...
SeekingAlpha
The Headwaters Capital Management portfolio gained +7.5% during Q2 2025 compared to a +8.5% gain for the Russell Mid Cap Index over the same period.
Current Value
$53.371 Year Return
Current Value
$53.371 Year Return
